产前抑制宫缩对新生儿结局的影响。
Effect of antenatal tocolysis on neonatal outcomes.
作者信息
Klauser Chad K, Briery Christian M, Keiser Sharon D, Martin Rick W, Kosek Mary A, Morrison John C
机构信息
Department of Obstetrics and Gynecology, The Mount Sinai Medical Center, New York City, NY, USA.
出版信息
J Matern Fetal Neonatal Med. 2012 Dec;25(12):2778-81. doi: 10.3109/14767058.2012.714819. Epub 2012 Aug 20.
OBJECTIVE
Detail adverse neonatal effects in pregnancies treated with indomethacin (I), magnesium sulfate (M) or nifedipine (N).
METHODS
Women in acute preterm labor with cervical dilatation 1-6 cm were randomized to receive one of three first-line tocolytic drugs.
RESULTS
There were 317 neonates (I = 103, M = 95, N = 119) whose mothers were treated with tocolytic therapy. There was no difference in gestational age at randomization (average 28.6 weeks' gestation) or at delivery (31.6 weeks' gestation, p = 0.551), birth weight (p = 0.871) or ventilator days (p = 0.089) between the three groups. Neonatal morbidity was not different between the three groups; respiratory distress syndrome (p = 0.086), patent ductus arteriosus (p = 0.592), sepsis (p = 0.590), necrotizing enterocolitis (p = 0.770), intraventricular hemorrhage (p = 0.669) and periventricular leukomalacia (p = 0.124).
CONCLUSIONS
There were no statistically significant differences between the three tocolytics as far as composite neonatal morbidity or mortality was concerned.
目的
详细阐述使用吲哚美辛（I）、硫酸镁（M）或硝苯地平（N）治疗的妊娠中新生儿的不良影响。
方法
宫颈扩张1 - 6厘米的急性早产妇女被随机分配接受三种一线宫缩抑制剂药物之一。
结果
有317名新生儿（I组 = 103名，M组 = 95名，N组 = 119名），其母亲接受了宫缩抑制治疗。三组在随机分组时的孕周（平均妊娠28.6周）、分娩时的孕周（妊娠31.6周，p = 0.551）、出生体重（p = 0.871）或呼吸机使用天数（p = 0.089）方面无差异。三组之间的新生儿发病率无差异；呼吸窘迫综合征（p = 0.086）、动脉导管未闭（p = 0.592）、败血症（p = 0.590）、坏死性小肠结肠炎（p = 0.770）、脑室内出血（p = 0.669）和脑室周围白质软化（p = 0.124）。
结论
就综合新生儿发病率或死亡率而言，三种宫缩抑制剂之间无统计学显著差异。
Zotero 插件